Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 - Wikidata - wikimedia - TriplyDB

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

http://www.wikidata.org/entity/Q37157688

about

Hepatotoxicity Secondary to Chemotherapy First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function Evolving role of Sorafenib in the management of hepatocellular carcinoma.Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.Population pharmacokinetic analysis of sorafenib in patients with solid tumours.Targeted therapy in hepatocellular carcinoma Sorafenib exerts anti-glioma activity in vitro and in vivo.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Sorafenib in advanced melanoma: a critical role for pharmacokinetics?The discovery and development of sorafenib for the treatment of thyroid cancer.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Sorafenib: where do we go from here?Adjuvant sorafenib for liver cancer: wrong stage, wrong dose Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.Methodological assessment of HCC literature National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma.Toxicity of sorafenib: clinical and molecular aspects.Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.Sorafenib for the management of advanced renal cell carcinoma.Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.

P2860

Q26861560-63C3F8C5-13BE-4FC5-A2C4-1CA17DE8339A Q28073654-46688520-D9AA-40FE-9108-7C1D2EB32F38 Q28079378-3FA38F99-B55C-4668-BBAA-29C3622B0466 Q28729059-01CDF012-DC2D-452D-A21F-548C06D171C2 Q33391851-1FC5ED42-1418-4B8D-9818-7A0AE25D7F43 Q33400837-ACCD683A-7246-4751-8944-4BF82AD1CAC4 Q33406591-0480239A-AFA8-4332-AC09-487DE757B735 Q33411001-60392937-7948-4C86-BCD9-5B2FA8F0F2BD Q33593207-464B82B3-8DAA-4271-98CF-F951CA6CA9D1 Q33779864-AA51BD8A-A96D-4022-AEF8-5FD3E70A8257 Q33794350-5BCDB9DA-EF65-42D1-B60E-5EEA80E54B1A Q34041554-E97EA90E-3E66-4D98-AD74-2DC0A826AF9F Q34161033-DE061DFA-FA25-4DD2-A832-A4FF6912DE85 Q34257497-F1436A95-983C-425C-84DD-C8D7A67396D6 Q34409128-1EE8D711-DC43-446A-9549-3B3E4CCC0E2E Q34668974-B080B8C2-A415-4B71-AE04-4AC12E07E5ED Q35030418-1A897667-C5BF-4CCC-93D8-6DEEFA1B75A4 Q35167764-47E08724-6759-4472-B9AE-F1173A09D202 Q35183640-DF84C1B7-2CC1-4B51-A88D-024A2E21D3DD Q35207561-AF6DF19F-F0B7-4870-A41E-EFC3B4B34662 Q35414966-9D274E86-D251-46EA-9672-64505D683AF1 Q35932561-34F19FCA-9565-404C-AFB3-7ED8FBB6FE8A Q36117220-D17E7B92-D3FD-44B6-9926-A3DFA4766910 Q36263304-697D30A7-07D5-4BDD-9510-6E008ED8FD87 Q36270115-9B3A6C47-4228-4148-A6A2-C839D31C174B Q36708741-E10DB326-A57E-4066-89CB-6576C3C351BC Q36739406-F3BD91A8-5CE1-457D-BE46-5A6063007971 Q36852518-798FFF50-E6AE-4A02-80B3-DF8B791BAB87 Q36963820-72DB36B0-C285-45FA-A018-A7518E931F74 Q37000692-CB996DE9-3EC0-440C-8DB7-483FED59181E Q37166427-AA145485-C739-40D3-B4A1-8F89031E2DD7 Q37283736-8979A111-AB80-4E6D-A18B-F768BCAFA1A8 Q37536010-3083D6D4-DFF0-491C-AA83-0FD5D69114D2 Q37676226-5DD882C6-E905-425A-B699-C4B61B733D82 Q37724256-825D0453-56A7-41D0-B638-58434F41B960 Q37765584-12C82270-C6D3-4740-812C-A4D0D6BC1604 Q37768896-E84ACCAB-1F53-443B-B8FE-29CF4ADF3388 Q37809571-B87A8A0C-79D3-42FE-9B88-30287E3D9466 Q37894667-CB441C9B-188D-43E3-A730-31F3381099DB Q37905601-93ABB925-7A47-4191-88CB-1B34F47AFEBA

P2860

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

http://www.wikidata.org/entity/Q37157688

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase I and pharmacokinetic st ...... renal dysfunction: CALGB 60301

@en

Phase I and pharmacokinetic st ...... enal dysfunction: CALGB 60301.

@nl

type

label

Phase I and pharmacokinetic st ...... renal dysfunction: CALGB 60301

@en

Phase I and pharmacokinetic st ...... enal dysfunction: CALGB 60301.

@nl

prefLabel

Phase I and pharmacokinetic st ...... renal dysfunction: CALGB 60301

@en

Phase I and pharmacokinetic st ...... enal dysfunction: CALGB 60301.

@nl

P1433

Q37157688-BC51E1B6-EA65-4255-99D3-CC8A423FF484

P1476

Q37157688-B4434EDC-1505-4927-BE6E-A86F1F38EEC1

P2093

Q37157688-2D076B6E-6FCC-4CF8-B59E-2497FA673205

Q37157688-353271EF-3A91-4C11-BD09-09571EEC5E48

Q37157688-49428CEB-017E-4507-BC9A-39324AA2CF84

Q37157688-5566267E-6CC6-4344-B966-CAA85032A963

Q37157688-62B0D870-67AC-4E30-948E-22CC7C208679

Q37157688-6C39DE33-85FA-4416-94D9-32283EE1D5CC

Q37157688-6E01232A-ACE6-4F73-A2A6-460953289029

Q37157688-6F3E5726-DC0D-43AF-987F-A49206040CFB

Q37157688-8B19C7DE-7160-4135-B9A0-D0B819200268

Q37157688-99665894-C956-46B6-99A8-C35C8FB83EAD

P2860

Q37157688-0B71AEF0-75CD-434A-BBF3-7A1E2E68F811

Q37157688-2ACEC168-97FA-48BE-9A72-110AE5686C8C

Q37157688-2FA9D2BE-16E6-42C1-94D4-B16DFB33C6B7

Q37157688-3586457A-51A5-4614-858E-862A9CC9F409

Q37157688-371D77E9-785E-4525-9984-B324CF00F451

Q37157688-6286384E-CF2E-48CD-BCA0-876B6A0E6B10

Q37157688-676E3748-FDAD-41A4-A306-8503B0E09936

Q37157688-6B774969-B7EA-41B7-A74E-AFB68074900A

Q37157688-6E01D9BD-0FBB-4894-877A-9948AB4BF903

Q37157688-7329F693-20C5-4721-ABC2-EA51A9AC0F88

P304

Q37157688-C9F34109-8586-4CF4-90C3-D9CB42A0B3B4

P31

Q37157688-C81515AE-1A89-4568-9360-8F231C5B0473

P356

Q37157688-91614E80-DB9F-4F1F-AB8A-4CA757FC6AC7

P407

Q37157688-09C748A5-1B9E-4EB6-A859-DCD289AAAA35

P433

Q37157688-B606D691-7902-49FF-B8D3-30E14BE3942E

P478

Q37157688-8216E7A2-118A-4864-AFA7-CD5CB4FCCC93

P50

Q37157688-A4CCDB3C-D673-49F5-B65A-1EE055825385

P577

Q37157688-5FAA2223-172B-4854-B9A7-AF639A33E5BA

P5875

Q37157688-94159054-8DF3-49C9-BA23-A2AC2184AF1A

P698

Q37157688-E2ACF895-AB98-4FCB-814C-666B2D5BB3AD

P921

Q37157688-944924E3-960F-423C-84CA-786616A05877

P932

Q37157688-EBB6CEAC-43E3-43BC-91F1-578D619C2102

P356

JCO.2008.20.0931

P1433

Journal of Clinical Oncology

P1476

Phase I and pharmacokinetic st ...... renal dysfunction: CALGB 60301

@en

P2093

Antonius A Miller

http://www.w3.org/2001/XMLSchema#string

Apurva Desai

http://www.w3.org/2001/XMLSchema#string

Daryl J Murry

http://www.w3.org/2001/XMLSchema#string

Donna R Hollis

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Erin B Kennedy

http://www.w3.org/2001/XMLSchema#string

Fred Millard

http://www.w3.org/2001/XMLSchema#string

Ghassan Abou-Alfa

http://www.w3.org/2001/XMLSchema#string

Jimmy Hwang

http://www.w3.org/2001/XMLSchema#string

Kouros Owzar

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Prediction of creatinine clearance from serum creatinine

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

Transection of the oesophagus for bleeding oesophageal varices.

BAY 43-9006 inhibition of oncogenic RET mutants.

Raf: a strategic target for therapeutic development against cancer.

P304

1800-1805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.0931

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24171673

http://www.w3.org/2001/XMLSchema#string

P698

19255312

http://www.w3.org/2001/XMLSchema#string

P921

P932

2668705

http://www.w3.org/2001/XMLSchema#string